Cyclophosphamide

Generic Name
Cyclophosphamide
Brand Names
Procytox
Drug Type
Small Molecule
Chemical Formula
C7H15Cl2N2O2P
CAS Number
50-18-0
Unique Ingredient Identifier
6UXW23996M
Background

Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cance...

Indication

Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patien...

Associated Conditions
Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma
Associated Therapies
-
Clinical Trials
Related News

Comparing the Efficacy of VHAG and Traditional Chemotherapy Regimens in Newly Diagnosed ETP-ALL

First Posted Date
2024-04-11
Last Posted Date
2024-04-29
Lead Sponsor
First Affiliated Hospital of Zhejiang University
Target Recruit Count
81
Registration Number
NCT06361329
Locations
🇨🇳

The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China

Dose Escalation and Expansion Study of TROP2 CAR Engineered IL-15- Transduced Cord Blood-derived NK Cells in Combination With Cetuximab in Patient With Colorectal Cancer (CRC) With Minimal Residual Disease (MRD)

First Posted Date
2024-04-10
Last Posted Date
2024-12-12
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
42
Registration Number
NCT06358430
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma

First Posted Date
2024-04-10
Last Posted Date
2024-12-18
Lead Sponsor
Celgene
Target Recruit Count
850
Registration Number
NCT06356129
Locations
🇺🇸

Cancer Care Specialists, Reno, Nevada, United States

🇺🇸

Local Institution - 0498, East Brunswick, New Jersey, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

and more 344 locations

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells

First Posted Date
2024-04-04
Last Posted Date
2024-10-26
Lead Sponsor
UNC Lineberger Comprehensive Cancer Center
Target Recruit Count
42
Registration Number
NCT06347068
Locations
🇺🇸

University of North Carolina, Chapel Hill, North Carolina, United States

High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

First Posted Date
2024-04-03
Last Posted Date
2024-11-05
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
30
Registration Number
NCT06345495
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies

First Posted Date
2024-04-02
Last Posted Date
2024-12-11
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
54
Registration Number
NCT06343376
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Phase 1 Clinical Trial to Evaluate the Safety and Anti-Tumor Activity of AB-201

First Posted Date
2024-04-02
Last Posted Date
2024-08-21
Lead Sponsor
GC Cell Corporation
Target Recruit Count
48
Registration Number
NCT06341647
Locations
🇦🇺

The Alfred Hosptial, Melbourne, Victoria, Australia

🇦🇺

Austin Hosptial, Melbourne, Victoria, Australia

🇦🇺

Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia

Ma-Spore ALL 2020 Study

First Posted Date
2024-03-28
Last Posted Date
2024-03-28
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
500
Registration Number
NCT06336395
Locations
🇲🇾

University Malaya Medical Centre, Kuala Lumpur, Malaysia

🇲🇾

Subang Jaya Medical Centre, Kuala Lumpur, Malaysia

🇸🇬

KK Women's and Children's Hospital, Singapore, Singapore

CAR T-cell Therapy Directed to CD70 for Pediatric Patients With Hematological Malignancies

First Posted Date
2024-03-22
Last Posted Date
2024-12-17
Lead Sponsor
St. Jude Children's Research Hospital
Target Recruit Count
24
Registration Number
NCT06326463
Locations
🇺🇸

St. Jude Children's Research Hospital, Memphis, Tennessee, United States

TCR Reserved and Power3 Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

First Posted Date
2024-03-21
Last Posted Date
2024-12-02
Lead Sponsor
Chinese PLA General Hospital
Target Recruit Count
30
Registration Number
NCT06323525
Locations
🇨🇳

Biotherapeutic Department of Chinese PLA General Hospital, Beijing, China

🇨🇳

School of Life Sciences, Peking University, Beijing, China

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy